Suppr超能文献

非诺贝特与血脂康对高脂饮食诱导的非酒精性脂肪性肝病的影响。

Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.

作者信息

Hong Xue Zhi, Li Lian Da, Wu Li Mao

机构信息

Institute of Chinese Herb Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, PR China.

出版信息

Clin Exp Pharmacol Physiol. 2007 Jan-Feb;34(1-2):27-35. doi: 10.1111/j.1440-1681.2007.04547.x.

Abstract
  1. Fenofibrate and xuezhikang are two types of drugs widely used in the treatment of dyslipidaemia in China. The main purpose of present study was to test the efficacies and explore the potential mechanisms of action of the two lipid-lowering agents on high-fat diet-induced non-alcoholic fatty liver disease (NAFLD). 2. Rats were randomly divided into four groups, with eight rats per group. One group was given normal diet, whereas the other three groups were fed a high-fat diet. Forty-two days later, two of the high-fat diet-fed groups were administered fenofibrate (100 mg/kg, p.o.) and xuezhikang (300 mg/kg, p.o.) for another 42 consecutive days. The other two groups were administered placebo (saline) by gavage. 3. Typical pathological symptoms of NAFLD occurred in the high-fat diet groups. Fenofibrate and xuezhikang treatment markedly improved NAFLD, ameliorating dyslipidaemia and fat accumulation in the liver, improving insulin resistance and ameliorating oxidative stress. Hepatic steatosis, necro-inflammation and collagen deposition were lessened in the drug-treated groups. However, both xuezhikang and fenofibrate failed to reverse hepatomegaly and fenofibrate even aggravated it. Xuezhikang reversed aminotransferase abnormalities, but fenofibrate had less of an effect. 4. The common therapeutic mechanism of action of fenofibate and xuezhikang likely involves inhibition of the hepatic expression of tumour necrosis factor-alpha. Fenofibrate upregulated mRNA levels of peroxisome proliferator-activated receptor (PPAR) alpha in the liver, whereas xuezhikang had no effect on the hepatic expression of PPARalpha and this may explain, in part, their different effects on the NAFLD rats. 5. The results suggest that fenofibrate and xuezhikang may have potential clinical application in the treatment of NAFLD. However, the side-effects of fenofibrate and the underlying constituents of xuezhikang need to be determined and investigated further.
摘要
  1. 非诺贝特和血脂康是中国广泛用于治疗血脂异常的两类药物。本研究的主要目的是测试这两种降脂药物对高脂饮食诱导的非酒精性脂肪性肝病(NAFLD)的疗效,并探索其潜在作用机制。2. 将大鼠随机分为四组,每组8只。一组给予正常饮食,而其他三组给予高脂饮食。42天后,高脂饮食组中的两组分别连续42天给予非诺贝特(100mg/kg,口服)和血脂康(300mg/kg,口服)。另外两组通过灌胃给予安慰剂(生理盐水)。3. 高脂饮食组出现了NAFLD的典型病理症状。非诺贝特和血脂康治疗显著改善了NAFLD,改善了血脂异常和肝脏脂肪堆积,改善了胰岛素抵抗并减轻了氧化应激。药物治疗组的肝脂肪变性、坏死性炎症和胶原沉积减少。然而,血脂康和非诺贝特均未能逆转肝肿大,非诺贝特甚至使其加重。血脂康逆转了转氨酶异常,但非诺贝特的作用较小。4. 非诺贝特和血脂康的共同治疗作用机制可能涉及抑制肝脏肿瘤坏死因子-α的表达。非诺贝特上调了肝脏中过氧化物酶体增殖物激活受体(PPAR)α的mRNA水平,而血脂康对肝脏PPARα的表达没有影响,这可能部分解释了它们对NAFLD大鼠的不同作用。5. 结果表明,非诺贝特和血脂康在NAFLD治疗中可能具有潜在的临床应用价值。然而,非诺贝特的副作用以及血脂康的潜在成分需要进一步确定和研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验